Calcium Gluceptate

Identification

Name
Calcium Gluceptate
Accession Number
DB00326  (APRD00841)
Type
Small Molecule
Groups
Approved
Description

Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium. They are used to prevent or treat several conditions that may cause hypocalcemia (not enough calcium in the blood). The body needs calcium to make strong bones. Calcium is also needed for the heart, muscles, and nervous system to work properly.

Structure
Thumb
Synonyms
  • Calcii Glucoheptonas
  • Calcii glugoheptonas
  • Calcium (2XI)-D-gluco-heptonate
  • Calcium bis[(2XI)-D-glycero-D-gulo-heptonate]
  • Calcium bis[(2XI)-D-glycero-D-ido-heptonate]
  • Calcium bis[(3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoate]
  • Calcium Gluceptate
  • Calcium glucoheptonat
  • Calcium glucoheptonate
  • Calcium glucoheptonate (1:2)
  • Glucoheptonate de calcium
  • Glucoheptonato calcico
  • Trimethylene chlorobromide
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Liq AlsiLiquid125 mgOralAlsi Cie Ltee1980-12-312003-05-21Canada
Sirop De Calcium 625mg/5mlSyrup625 mgOralTherapex Division De E Z Em Canada Inc1980-12-311997-07-22Canada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GlucoheptonateInjection, powder, lyophilized, for solution50 mg/1IntravenousAnazao Health Corporation2012-05-23Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Calcium LiquidCalcium Gluceptate (132 mg) + Calcium gluconate (112 mg)LiquidOralKsl Pharmaceuticals1994-12-311996-09-09Canada
Calcium LiquidCalcium Gluceptate (132 mg) + Calcium gluconate (112 mg)LiquidOralShoppers Drug Mart Inc.1981-12-311997-08-15Canada
Calcium LiquidCalcium Gluceptate (132 mg) + Calcium gluconate (112 mg)LiquidOralVita Health Products Inc1980-12-312002-07-31Canada
Liquid CalciumCalcium Gluceptate (132 mg) + Calcium gluconate (112 mg)LiquidOralWampole Brands, A Division Of Pangeo Pharma (Canada) Inc.1998-08-122000-07-06Canada
Categories
UNII
L11651398J
CAS number
29039-00-7
Weight
Average: 490.425
Monoisotopic: 490.084675939
Chemical Formula
C14H26CaO16
InChI Key
FATUQANACHZLRT-KMRXSBRUSA-L
InChI
InChI=1S/2C7H14O8.Ca/c2*8-1-2(9)3(10)4(11)5(12)6(13)7(14)15;/h2*2-6,8-13H,1H2,(H,14,15);/q;;+2/p-2/t2*2-,3-,4+,5-,6?;/m11./s1
IUPAC Name
calcium bis((3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoate)
SMILES

Pharmacology

Indication

For treatment of mild hypocalcemia due to neonatal tetany, tetany due to parathyroid deficiency or vitamin D deficiency, and alkalosis, as prophylaxis of hypocalcemia during exchange transfusions, in the treatment of intestinal malabsorption, and to replenish electrolytes.

Structured Indications
Not Available
Pharmacodynamics

Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium. They are used to prevent or treat several conditions that may cause hypocalcemia (not enough calcium in the blood). The body needs calcium to make strong bones. Calcium is also needed for the heart, muscles, and nervous system to work properly. The bones serve as a storage site for the body's calcium. They are continuously giving up calcium to the bloodstream and then replacing it as the body's need for calcium changes from day to day. When there is not enough calcium in the blood to be used by the heart and other organs, your body will take the needed calcium from the bones. When you eat foods rich in calcium, the calcium will be restored to the bones and the balance between your blood and bones will be maintained.

Mechanism of action

Calcium gluceptate replenishes the deminished levels of calcium in the body, returning them to normal levels.

Absorption

Rapidly absorbed following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include confusion, drowsiness (severe), high blood pressure, increased sensitivity of eyes or skin to light, irregular, fast, or slow heartbeat, and unusually large amount of urine or increased frequency of urination.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinCalcium Gluceptate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinCalcium Gluceptate may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Gluceptate.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Gluceptate.Approved
AmrinoneThe therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium Gluceptate.Approved
AzelnidipineThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
AzimilideThe therapeutic efficacy of Azimilide can be decreased when used in combination with Calcium Gluceptate.Investigational
BarnidipineThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium Gluceptate.Approved
BencyclaneThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium Gluceptate.Experimental
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
BenidipineThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Gluceptate.Approved, Withdrawn
CalcidiolThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Calcipotriol.Approved
Calcium AcetateThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Calcium Acetate.Approved
CarboxyamidotriazoleThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium Gluceptate.Investigational
CaroverineThe therapeutic efficacy of Caroverine can be decreased when used in combination with Calcium Gluceptate.Experimental
CeftriaxoneThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Ceftriaxone.Approved
ChlorothiazideChlorothiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved, Vet Approved
ChlortetracyclineThe serum concentration of Chlortetracycline can be decreased when it is combined with Calcium Gluceptate.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
CilnidipineThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
CinnarizineThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
CinoxacinCalcium Gluceptate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
ClevidipineThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Calcium Gluceptate.Approved, Investigational, Vet Approved
CyclopenthiazideCyclopenthiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Experimental
CymarinCalcium Gluceptate may increase the arrhythmogenic activities of Cymarin.Experimental
DarodipineThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Gluceptate.Experimental
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Calcium Gluceptate.Approved
DemeclocyclineThe serum concentration of Demeclocycline can be decreased when it is combined with Calcium Gluceptate.Approved
DeslanosideCalcium Gluceptate may increase the arrhythmogenic activities of Deslanoside.Approved
DigitoxinCalcium Gluceptate may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinCalcium Gluceptate may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Calcium Gluceptate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Dihydrotachysterol.Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Calcium Gluceptate.Approved
Dipotassium phosphateCalcium Gluceptate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Gluceptate.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium Gluceptate.Approved
DotarizineThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium Gluceptate.Investigational
DoxercalciferolThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Doxercalciferol.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Calcium Gluceptate.Approved, Investigational, Vet Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Calcium Gluceptate.Approved
EnoxacinCalcium Gluceptate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EperisoneThe therapeutic efficacy of Eperisone can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
ErgocalciferolThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Ergocalciferol.Approved, Nutraceutical
EstramustineCalcium Gluceptate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Calcium Gluceptate.Approved
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
FendilineThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium Gluceptate.Withdrawn
FleroxacinCalcium Gluceptate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlumequineCalcium Gluceptate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium Gluceptate.Approved
GabapentinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
GallopamilThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium Gluceptate.Investigational
GarenoxacinCalcium Gluceptate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinCalcium Gluceptate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemifloxacinCalcium Gluceptate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GitoformateCalcium Gluceptate may increase the arrhythmogenic activities of Gitoformate.Experimental
GrepafloxacinCalcium Gluceptate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational, Withdrawn
HydrochlorothiazideHydrochlorothiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved, Investigational
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Gluceptate.Approved, Investigational
IndapamideIndapamide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium Gluceptate.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
Lanatoside CCalcium Gluceptate may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
LevofloxacinCalcium Gluceptate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium Gluceptate.Approved
LidoflazineThe therapeutic efficacy of Lidoflazine can be decreased when used in combination with Calcium Gluceptate.Experimental
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium Gluceptate.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Calcium Gluceptate.Approved
Lipoic AcidCalcium Gluceptate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
Magnesium SulfateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Gluceptate.Approved, Vet Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
MethyclothiazideMethyclothiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
MetildigoxinCalcium Gluceptate may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetolazoneMetolazone may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Calcium Gluceptate.Investigational, Withdrawn
MinocyclineThe serum concentration of Minocycline can be decreased when it is combined with Calcium Gluceptate.Approved, Investigational
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Gluceptate.Investigational
Nalidixic AcidCalcium Gluceptate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NemonoxacinCalcium Gluceptate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Gluceptate.Approved
NifedipineThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Gluceptate.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Gluceptate.Experimental
NiludipineThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium Gluceptate.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
NimesulideThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Gluceptate.Approved
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Gluceptate.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
NorfloxacinCalcium Gluceptate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OleandrinCalcium Gluceptate may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Calcium Gluceptate.Experimental, Investigational
OuabainCalcium Gluceptate may increase the arrhythmogenic activities of Ouabain.Approved
Oxolinic acidCalcium Gluceptate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium Gluceptate.Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Paricalcitol.Approved, Investigational
PazufloxacinCalcium Gluceptate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinCalcium Gluceptate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PerhexilineThe therapeutic efficacy of Perhexiline can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
PeruvosideCalcium Gluceptate may increase the arrhythmogenic activities of Peruvoside.Experimental
PinaveriumThe therapeutic efficacy of Pinaverium can be decreased when used in combination with Calcium Gluceptate.Approved
Pipemidic acidCalcium Gluceptate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidCalcium Gluceptate can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PolythiazidePolythiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
PregabalinThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium Gluceptate.Approved, Illicit, Investigational
PrenylamineThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium Gluceptate.Withdrawn
ProscillaridinCalcium Gluceptate may increase the arrhythmogenic activities of Proscillaridin.Experimental
PrulifloxacinCalcium Gluceptate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
QuinethazoneQuinethazone may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Gluceptate.Approved, Investigational
RosoxacinCalcium Gluceptate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RufloxacinCalcium Gluceptate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SitafloxacinCalcium Gluceptate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateCalcium Gluceptate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateCalcium Gluceptate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinCalcium Gluceptate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Calcium Gluceptate.Approved
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Calcium Gluceptate.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Calcium Gluceptate.Approved
TemafloxacinCalcium Gluceptate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TerodilineThe therapeutic efficacy of Terodiline can be decreased when used in combination with Calcium Gluceptate.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Gluceptate.Investigational
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Calcium Gluceptate.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Calcium Gluceptate.Approved, Investigational, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Gluceptate.Approved
TranilastThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Gluceptate.Approved, Investigational
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Triethylenetetramine can be decreased when it is combined with Calcium Gluceptate.Approved
TrovafloxacinCalcium Gluceptate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
VerapamilThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Gluceptate.Approved
VinpocetineThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium Gluceptate.Investigational
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium Gluceptate.Approved
ZiconotideThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Gluceptate.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Calcium Gluceptate.Approved
Food Interactions
Not Available

References

General References
  1. Drop LJ, Cullen DJ: Comparative effects of calcium chloride and calcium gluceptate. Br J Anaesth. 1980 May;52(5):501-5. [PubMed:7387803]
External Links
Human Metabolome Database
HMDB14471
KEGG Drug
D00934
PubChem Compound
62859
PubChem Substance
46507233
ChemSpider
56591
ChEBI
3314
ChEMBL
CHEMBL1237066
PharmGKB
PA164746233
ATC Codes
A12AA10 — Calcium glucoheptonate
MSDS
Download (68.6 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Abbott laboratories pharmaceutical products div
  • Abraxis pharmaceutical products
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
LiquidOral125 mg
LiquidOral
Injection, powder, lyophilized, for solutionIntravenous50 mg/1
SyrupOral625 mg
Prices
Unit descriptionCostUnit
Calcium gluceptate powder12.69USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
Predicted Properties
PropertyValueSource
Water Solubility39.8 mg/mLALOGPS
logP-1.9ALOGPS
logP-4ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)3.38ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area161.51 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity55.07 m3·mol-1ChemAxon
Polarizability19.35 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9575
Blood Brain Barrier+0.5646
Caco-2 permeable-0.8513
P-glycoprotein substrateNon-substrate0.6616
P-glycoprotein inhibitor INon-inhibitor0.9743
P-glycoprotein inhibitor IINon-inhibitor0.9608
Renal organic cation transporterNon-inhibitor0.9445
CYP450 2C9 substrateNon-substrate0.8702
CYP450 2D6 substrateNon-substrate0.87
CYP450 3A4 substrateNon-substrate0.7334
CYP450 1A2 substrateNon-inhibitor0.8579
CYP450 2C9 inhibitorNon-inhibitor0.9163
CYP450 2D6 inhibitorNon-inhibitor0.9286
CYP450 2C19 inhibitorNon-inhibitor0.9106
CYP450 3A4 inhibitorNon-inhibitor0.9274
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9873
Ames testNon AMES toxic0.8429
CarcinogenicityNon-carcinogens0.838
BiodegradationReady biodegradable0.9895
Rat acute toxicity1.9804 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9838
hERG inhibition (predictor II)Non-inhibitor0.938
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as sugar acids and derivatives. These are compounds containing a saccharide unit which bears a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Sugar acids and derivatives
Alternative Parents
Heptoses / Medium-chain hydroxy acids and derivatives / Medium-chain fatty acids / Beta hydroxy acids and derivatives / Hydroxy fatty acids / Secondary alcohols / Carboxylic acid salts / Polyols / Organic calcium salts / Monocarboxylic acids and derivatives
show 6 more
Substituents
Heptose monosaccharide / Medium-chain hydroxy acid / Medium-chain fatty acid / Beta-hydroxy acid / Hydroxy fatty acid / Sugar acid / Fatty acyl / Fatty acid / Hydroxy acid / Monosaccharide
show 15 more
Molecular Framework
Not Available
External Descriptors
calcium salt (CHEBI:3314)

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:36